Introduction
============

Lower urinary tract symptom (LUTS) suggestive of benign prostatic hyperplasia (BPH) is a common condition among middle-aged to elderly men. It is characterized by a cluster of chronic urinary symptoms in the bladder, prostate, and a major cause of benign prostatic hyperplasia. Population based studies suggested that nearly one in every four men aged 50 and above is affected by LUTS ([@B14]). Similarly, a recent study found that 69.3% of community-dwelling men experienced moderate-to-severe symptoms on International Prostate Symptom Score (IPSS) in Hong Kong ([@B30]). Without proper treatment, LUTS can present with complications, such as acute urinary retention (AUR), urinary tract infections, or sometimes obstructive uropathy ([@B16];[@B19]). In the current era of an increased life expectancy and the aging of baby boomer generation, male LUTS would become an issue of increasing socioeconomic and medical importance ([@B15]; [@B11]; [@B14]).

The main pharmacological agents for the management of LUTS are alpha-blockers and 5-alpha-reductase inhibitors (5ARIs). Currently, international guidelines ([@B19]; [@B21]) recommend the use of alpha-blockers for symptomatic relief in LUTS patients who do not have a markedly enlarged prostate, while highlighting that these agents do not alter the natural progression of the disease. On the other hand, 5ARIs, which can be administered as monotherapy or in combination with alpha-blockers, are recommended for symptomatic men with an enlarged prostate and are associated with decreased risk of urinary retention and related surgery. One of the major trials to support such recommendation is the Combination of Avodart^TM^ (dutasteride) and tamsulosin (CombAT) trial ([@B23], [@B22]). In this randomized- multicenter, double-blind, parallel-group study of 50 years or older men with a clinical diagnosis of moderate to severe BPH, a single-dose tamsulosin/dutasteride combination therapy was compared with tamsulosin and dutasteride monotherapies. It was found that patients with a prostate volume ≥40 ml had a lower risk of disease progression, AUR, and BPH-related surgery in the groups receiving dutasteride or combination therapies than in the group receiving tamsulosin monotherapy.

In terms of economic burden, BPH/LUTS is associated with high personal and societal costs, which are evident in direct medical costs and indirect losses in daily functioning, and through its negative impact on quality of life (QoL) for both patients and partners ([@B15]; [@B25]). Treatment and interventions for BPH/LUTS are essential, which aim at providing symptom relief as well as addressing the root cause, while limiting the occurrence of adverse events. As the prevalence of BPH/LUTS increases with age, the burden on the healthcare system and society may increase due to the aging population ([@B24]; [@B14]). In the United Kingdom, it was estimated that more than \$180 million was spent on BPH treatments each year ([@B25]). In 2000, it was estimated that the direct cost of medical services for BPH in the United Sates was about US\$1.1 billion ([@B29]). In Hong Kong, the per capita total expenditure on health in 2010/2011 was HK\$ 13302 (US\$ 1705) ([@B7]). Like many places around the world, the healthcare systems local and abroad face an increasing cost scrutiny. Cost-effectiveness assessment of treatments is gaining more importance to ensure patient satisfaction as well as the most efficient outcome in the environment of cost-containment.

In view of this, the objective of our study was to evaluate the long-term cost-effectiveness of oral, daily, single-dose combination therapy dutasteride/tamsulosin (Duodart^®^), compared with oral, daily tamsulosin 0.4 mg in Hong Kong (HK).

Materials and Methods {#s1}
=====================

Overview of the Economic Model
------------------------------

A Markov model was developed to project the overall cost-savings of combination therapy in a hypothetical cohort of 10,000 patients treated in the public healthcare sector of HK. As such, ethical approval was not obtained since no patient was involved in this research. The natural history of BPH progression has been widely examined in literature ([@B4]; [@B29]). As such, we used this as our base case to build our model. We subsequently had a discussion workshop to seek clinical experts' views on the disease progression pathway of BPH and to understand the use of different treatments in the local context. The workshop included review of international BPH management guidelines, exploration of consensus in the local clinical setting, as well as retrospective analysis of BPH outcome data from the territory. The model population is consistent with the entry criteria for the CombAT trial ([@B23]), i.e., the hypothetical cohort of patients ≥50 year of age with a BPH clinical diagnosis by medical history and physical examination. This age group was representative of BPH patient population in Asia and the most commonly studied age group in clinical trials.

The model was structured according to the HK-specific treatment practice, and is shown in **Figure [1](#F1){ref-type="fig"}**. In the beginning of the simulation, patients start from BPH state. As time progresses, patients might remain in BPH state, transition between the symptom states, experience AUR, receive a surgical intervention (TURP), or die due to natural causes. After experiencing an AUR episode, the patient could transition back to BPH state. After TURP, a patient would receive medical intervention or have a repeated TURP procedure if the initial surgical procedure is not successful. Patients who have undergone TURP could die due to complications of the procedure, or they could die due to other causes. A patient in TURP, repeated TURP or medical intervention state could recover back to healthy state.

![Model structure. ^\$^The death state includes patients who died from TURP and all-cause mortality.](fphar-09-01078-g001){#F1}

The analysis was performed from the healthcare payers' perspective, which only included direct costs. A cycle length of 1 year was adopted to capture the full effect of both intervention in terms of resource use and quality of life. In the base-case scenario, the model was simulated over 4 years, i.e., duration of the trial. To assess the sensitivity of the model results to the time horizon, the model was also run for 35 years, i.e., patients' life span. A discount rate of 3% was applied to both cost and outcome.

Assumptions
-----------

There are a few assumptions made in our model as described in the following:

1.  In reality, BPH state can be classified according to severity, i.e., mild, moderate, and severe states. However, due to the lack of granular data on symptom severity as measured by the International Prostate Symptom Score (IPSS) of BPH patients, we modeled patients into one BPH state;

2.  It is assumed that high proportion of acute urinary retention (AUR) patients (80%) will receive transurethral resection of the prostate (TURP) procedure. This uncertainty will be addressed using 1-way and multivariate probabilistic sensitivity analyses;

3.  Patients who recover from the first TURP procedure are assumed to incur only one follow-up cost. Medical intervention means the use of pharmacological agents for follow-up management;

4.  Post-TURP death due to TURP-related complications is defined as death which occurs within 30 days after TURP procedure;

5.  The second TURP procedure will require different amount of resources compared to the first TURP; Based on local literature, post-TURP death due to second TUPR is assumed to be the same as that from first TURP;

6.  It is assumed that patients will receive at most 2 TURP procedures.

Data Inputs
-----------

As summarized in **Table [1](#T1){ref-type="table"}**, model parameters including transition probabilities, efficacy, costs, and utilities were derived from HK-specific sources, literatures and assumptions based on clinical inputs.

###### 

Model inputs.

  Parameters                                                          Base-case   Range             Source
  ------------------------------------------------------------------- ----------- ----------------- ------------------------------------------------
  **Transition probability (monthly)**                                                              
  Remaining in BPH                                                    0.345       0.248--0.45       [@B3]
  BPH patients who experience TURP                                    0.021       0.0098--0.036     [@B3]
  AUR patients going through TURP                                     0.8         0.75--0.85        Prince of Wales Hospital^∧^
  TURP patients' 30-day mortality                                     0.0237      0.0179--0.0296    [@B20]
  TURP patients who recover                                           1           N/A               [@B20]
  TURP patients who require medical intervention                      0.059       N/A               Prince of Wales Hospital^%^
  TURP patients who require repeated surgical intervention            0.059       N/A               Prince of Wales Hospital^%^
  Patients with repeated TURP died from surgical procedure            0           N/A               Prince of Wales Hospital^%^
  Patients who remain at recovery state                               0.329       0.275--0.41       Prince of Wales Hospital
  Recovered patients who require medical intervention                 0.0467      0.0295--0.0744    Prince of Wales Hospital
  Patients on medication who require the second TURP                  0.036       0.0215--0.061     Prince of Wales Hospital
  Patients with repeated TURP requiring medication intervention       0.0025      N/A               Prince of Wales Hospital^%^
  Patients with repeated TURP who recover                             1           N/A               Prince of Wales Hospital^%^
  Patients remain on medication                                       0.393       0.378--0.438      Prince of Wales Hospital^%^
  TURP patients who fully recover                                     0.998       0.978--1          Prince of Wales Hospital^%^
  Patients on medication who transition to AUR state                  0                             [@B3]
  BPH patients who experience AUR                                     0.004       0.00064--0.0154   [@B3]
  All-cause mortality                                                                               HK life table
  **Efficacy (over 4 years)**                                                                       
  Efficacy of tamsulosin/dutasteride against AUR (vs. monotherapy)    0.676       0.527--0.778      [@B23]
  Efficacy of tamsulosin/dutasteride against TURP (vs. monotherapy)   0.706       0.577--0.795      [@B23]
  **Cost (per annum) (2018 US\$)**^@^                                                               
  tamsulosin/dutasteride                                              464.97      348--581          Hong Kong public hospital formulary estimation
  Tamsulosin                                                          55.79       41.8--69.7        Hong Kong public hospital formulary estimation
  Managing a patient who is initially in BPH moderate state           471         223--720          Prince of Wales Hospital^%^
  Managing a patient who experiences an episode of AUR                1312        590--4,199        Prince of Wales Hospital^%^
  TURP procedure                                                      6334        4,549--8,119      Prince of Wales Hospital^%^
  Managing a patient who requires medical intervention                371         123--620          Prince of Wales Hospital^%^
  **Utility**                                                                                       
  BPH mild                                                            0.993       0.94--1           [@B2]
  BPH moderate                                                        0.903       0.86--0.95        [@B2]
  BPH severe                                                          0.79        0.75--0.83        [@B2]
  BPH (weighted) (used in the model)^\$^                              0.876       0.83--0.92        [@B2]
  AUR                                                                 0.25        0.24--0.26        [@B6]
  TURP^\#^                                                            0.25        0.24--0.26        [@B6]
  Medical intervention                                                0.25        0.24--0.26        Assumption
  Recovery                                                            1.0         0.95--1           Assumption
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The majority of the transition probabilities were derived from a cohort of 200 BPH patients from Prince of Wales Hospital. Those patients comprised of roughly 10% of overall BPH patients in HK thus were considered representative of all BPH patients' profile in HK. The remaining probabilities were obtained from published literature where available. In addition to mortality due to TURP procedure, the model also allowed for patients to die from all-cause mortality which was obtained from HK life table. The efficacy of the different interventions were derived from a 4-years, multicentre, randomized, double-blind, parallel-group CombaT clinical trial which included 4,844 men ≥50 years of age with a clinical diagnosis of BPH, International Prostate Symptom Score ≥12 ([@B23]). The acquisition cost price of combination therapy and tamsulosin were US\$1.274 and US\$0.15 per tablet respectively based on the acquisition cost of Prince of Wales Hospital, which is a public hospital. The costs are relatively similar across all public hospitals in Hong Kong, which account for the care of majority of patients with BPH in the territory. Similarly, the costs of management of BPH, AUR, TURP, and medical intervention were all solicited from Prince of Wales Hospital. Quality of life (utility) values associated with each health state were extrapolated from two other BPH cost-effectiveness studies ([@B2]; [@B6]) as local utility study was not available. In the model, QALYs were calculated by applying the utility to the survival duration of a patient from his/her health state. There was significant reduction of utility for patients experiencing AUR and having TURP procedure compared with patients at BPH state.

Assessment Methods of Outcomes
------------------------------

Outcome measure is expressed as incremental cost per quality-adjusted life year (QALY) gained. As of now, there is no cost-effectiveness threshold in Hong Kong, 3 times Hong Kong GDP per capita 2017 (US\$45,887) recommended by WHO-CHOICE ([@B9]) The CHOICE (CHOosing Interventions that are Cost-Effective) was used to determine if the new intervention is cost-effective compared to the existing one ([@B8]).

Deterministic One-Way Sensitivity Analysis (OWSA)
-------------------------------------------------

To identify key model parameters, OWSA was conducted over the range of pre-defined values of each parameter's point estimate (i.e., 95% confidence interval). Results were plotted in a tornado diagram according to the extent of the parameter's impact on the incremental cost-effectiveness ratio (ICER).

Multivariate Probabilistic Sensitivity Analysis
-----------------------------------------------

To assess the simultaneous influence of model parameters on the ICER, a multivariate probabilistic sensitivity analysis was performed using second-order Monte Carlo simulation (computational algorithm based on repeated random sampling of the probability distributions for each model parameter). A total of 10,000 Monte-Carlo iterations were simulated, each generating a model-estimated value for the cost and QALY. The cost-effectiveness plane was produced depicting the scatterplot of the 10,000 simulated sets of cost and QALY estimates. In addition, a cost-effectiveness acceptability curve (CEAC) was generated to display the probability of cost-effectiveness of both interventions at each willingness-to-pay threshold. **Table [2](#T2){ref-type="table"}** presents the categories of model parameters, probability distributions as well as the upper and lower values used in the multivariate probabilistic sensitivity analysis.

###### 

Model inputs and their distributions used in multivariate probabilistic sensitivity analysis.

  Model parameter                                 Probability distribution   Distribution parameters   Mean/base case   LL       UL
  ----------------------------------------------- -------------------------- ------------------------- ---------------- -------- --------
  **Probabilities**                                                                                                              
  Probability ofBPH                               Beta                       α=0.62                    0.0208           0.0098   0.036
  patients who experience                                                    β=29.27                                             
  TURP                                                                                                                           
  Probability of patients                         Beta                       α=2.83 β=7.79             0.3295           0.275    0.41
  who still remain at                                                                                                            
  recovery state                                                                                                                 
  Probability of recovered                        Beta                       α=2.24                    0.0743           0.0295   0.0774
  patients who require                                                       β=27.97                                             
  medical intervention                                                                                                           
  Probability of patients                         Beta                       α=2.3 β=35.16             0.0614           0.0215   0.061
  on medication who                                                                                                              
  require the second TURP                                                                                                        
  Probability of BPH                              Beta                       α=0.06                    0.02             0.0032   0.075
  patients who experience                                                    β=2.9                                               
  AUR                                                                                                                            
  **Treatment effects for disease progression**                                                                                  
  Efficacy of                                     Beta                       α=1.77                    0.676            0.527    0.778
  tamsulosin/dutasteride                                                     β=0.85                                              
  against AUR                                                                                                                    
  Efficacy of                                     Beta                       α=2.5 β=1.04              0.706            0.577    0.795
                                                                                                                                 
  tamsulosin/dutasteride                                                                                                         
  against TURP                                                                                                                   
  **Cost**                                                                                                                       
  Managing a patient who                          Gamma                      α=3.61                    471              223      720
  is initially in BPH                                                        λ=0.01                                              
  moderate state                                                                                                                 
  Managing a patient who                          Gamma                      α=0.21 λ=1.57             1312             590      4,199
  experiences an episode                                                                                                         
  of AUR                                                                                                                         
  Managing a patient who                          Gamma                      α=12.59                   6334             4549     8119
  undergoes TURP                                                             λ=0.002                                             
  procedure                                                                                                                      
  Managing a patient who                          Gamma                      α=2.24? λ=0.006           371              123      620
                                                                                                                                 
  requires medical                                                                                                               
  intervention                                                                                                                   

LL, Lower limit; UL, Upper limit

.

The model was implemented in TreeAge pro 2017 (TreeAge Software, Williamstown, MA, United States). A microsimulation of 10,000 patients was executed to enable the tracking of the number of clinical events.

Results
=======

Base-Case Analysis
------------------

As shown in **Table [3](#T3){ref-type="table"}**, the Markov microsimulation based on 10,000 iterations showed that, over 4 years, compared to tamsulosin, combination therapy could prevent 0.03 AURs (∼27% reduction) per patient, 0.07 TURPs (∼32% reduction) per patient, and 0.002 deaths (∼3.5% reduction) over 4 years. Compared to tamsulosin, combination therapy can lead to cost reduction of US\$31, US\$1,029, and US\$2 per patient due to reduced episodes of AUR, TURP and need of medical intervention, respectively and additionally a delay in patient's progression to AUR and TURP. However, those benefits came with an incremental drug cost of US\$1,543 per patient over 4-year period. The increased number of BPH (3.43) for combination therapy compared to that (3.3) of monotherapy was mainly due to the delayed progression of BPH patients to AUR and TURP health states. In addition, the analysis showed that a patient on combination therapy would experience more QALYs (3 vs. 2.93 QALYs) than those on monotherapy. As a result, replacing monotherapy by combination therapy was expected to lead to US\$11,651 per QALY gained.

###### 

Base-case results.

                                                                  Combination therapy (a)   Monotherapy (b)   Difference (a-b)
  --------------------------------------------------------------- ------------------------- ----------------- ------------------
  *Model time horizon: 4 years*                                                                               
  **Average cost per patient of 10,000 population (US\$ 2018)**                                               
  Drug                                                            1,749                     206               1,543
  BPH                                                             1,935                     1,642             293
  AUR                                                             108                       139               -31
  TURP                                                            1,090                     2,119             -1,029
  Medical intervention                                            6                         8                 -2
  **Health outcomes per patient (by episode)**                                                                
  BPH                                                             3.43                      3.3               0.15
  AUR                                                             0.08                      0.11              -0.03
  TURP                                                            0.22                      0.29              -0.07
  Death                                                           0.056                     0.0577            -0.002
  QALY                                                            3.00                      2.93              0.07
  **Incremental cost-effectiveness ratio**                                                                    
  Cost per QALY gained                                            11,651                                      
  *Model time horizon: Life-time (35 years)*                                                                  
  **Average cost per patient of 10,000 population (US\$ 2018)**                                               
  Drug                                                            7,473                     856               6,617
  BPH                                                             5,224                     4,475             749
  AUR                                                             2,644                     3,095             -451
  TURP                                                            6,124                     11,594            -5,470
  Medical intervention                                            212                       249               -37
  **Health outcomes per patient (by episode)**                                                                
  BPH                                                             11.09                     9.5               1.59
  AUR                                                             2.01                      2.36              -0.35
  TURP                                                            2.25                      2.62              -0.37
  Death                                                           0.9675                    0.9784            0.0109
  QALY                                                            10.29                     9.87              0.42
  **Incremental cost-effectiveness ratio**                                                                    
  Cost per QALY gained                                            3,329                                       

As the modeling time horizon was extended to life-time, compared to monotherapy, more health benefits were projected for patients receiving combination therapy, i.e., a reduction of 0.35 AURs per patient, 0.37 TURPs per patient and 0.0109 deaths, which translated into 0.42 QALY gained per patient. In addition, using combination therapy at an incremental drug cost of US\$6,617 compared to tamsulosin could potentially save US\$451 per patient in managing AUR and US\$5,470 per patient in TURP procedure. Similarly, as the combination therapy reduced risks of a patient progressing to AUR and TURP health states, therefore, an incremental cost of US\$749 in managing BPH was incurred.

### Way Sensitivity Analysis

The OWSA showed that the top five most influential parameters on ICER were annual cost of tamsulosin/dutasteride, efficacy of tamsulosin/dutasteride against TURP, and probability of BPH patients who experienced AUR, cost of providing TURP procedure and utility of BPH. The remaining parameters had only a moderate influence on ICER estimates causing ICER to vary by no more than US\$2,000. On the whole, all the ICERs were found to be between US\$6,000 and US\$17,000 per QALY when parameters were varied over their uncertainty range (**Figure [2](#F2){ref-type="fig"}**).

![Tornado diagram for one-way sensitivity analysis. ^\#^The results were based on 4-year projection.](fphar-09-01078-g002){#F2}

Multivariate Probabilistic Sensitivity Analysis
-----------------------------------------------

The average incremental costs and QALYs over the 10,000 Monte Carlo simulations from the probabilistic sensitivity analysis were essentially similar compared to the deterministic base-case results. As shown in **Figure [3A](#F3){ref-type="fig"}**, over 4-year projection period, the scatterplots of incremental costs and QALYs for combination therapy vs. monotherapy showed that over 98% of the 10,000 Monte Carlo iterations fell within the north-east quadrant, suggesting that combination therapy produced higher QALYs at a higher cost, even with uncertainty in all parameters. In **Figure [3B](#F3){ref-type="fig"}**, over life-time horizon, there was a trend suggesting that combination therapy was cost-saving, i.e., less costly and more effective, among 12.8% of all 10,000 simulations while the remaining simulated results fell within the north-east quadrant.

![Cost-effectiveness scatterplot. **(A)** Cost effectiveness projection over 4 years. **(B)** Cost effectiveness projection over life-time.](fphar-09-01078-g003){#F3}

As shown in **Figure [4](#F4){ref-type="fig"}**, the CEAC showed that, over 4-year time horizon, it demonstrated that the probability of combination therapy being cost-effective was greater than 95% if willingness to pay (WTP) threshold is above US\$40,000. Besides, the combination therapy had a probability of 97% of being cost-effective over monotherapy at one time HK GDP per capita of US\$45,887. Over life-time projection, combination therapy would have a probability of cost-effectiveness of more than 95% if WTP threshold is above US\$20,000. It will achieve a probability of 99% being cost-effective at one time HK GDP per capita.

![Cost effectiveness acceptability curve. **(A)** Projection over a 4 year period. **(B)** Projection over lifetime period.](fphar-09-01078-g004){#F4}

Discussion
==========

Hong Kong's healthcare system comprises of the public and private sector, with the former being the cornerstone of the healthcare system, acting as a safety net for the population. The public system currently serves 90% of all inpatient needs and ∼30% of outpatient services ([@B12]). It has a very comprehensive range of services which are charged at very low rates, representing approximately 95% subsidy from the actual cost. Similar to many countries around the world, Hong Kong is currently facing serious challenges due to its rapidly aging population ([@B12]; [@B17]; [@B1]). It is estimated that the total population aged \>60 years in Hong Kong will rise from 12.5% currently to 25% in 2030, which will thus result in an increase in BPH prevalence. 5ARIs and alpha blockers, used either as monotherapy or combination therapy, are common modalities for BPH/LUTS treatment. While the results of the CombAT trial proved the clinical benefits of dutasteride/tamsulosin combination in symptom relief and reducing clinical progression of BPH ([@B23]), our model based on current drug price showed that patients who were treated with combination therapy experienced more QALYs but incurred higher costs than patients on background medications, leading to an ICER of US\$11,651 and US\$3,329 per QALY over 4-year and life-time horizon. Deterministic OWSA indicated that the results were most sensitive to the acquisition cost of combination therapy and drug efficacy.

It is worth noting that based on hospital data 80% of all patients with AUR would eventually go through the most common surgical procedure for BPH treatment, i.e., TURP. This is reflective of the reality as a small number of patients would not be fit for surgery due to various medical reasons, and besides TURP there are other surgical options for the management of TURP, e.g., laser prostatectomy. However, in the setting of the local health care system, TURP is still the majority. Such assumption for the construction of the Markov model would give a good estimation of the results.

Despite the differences in epidemiology and costs, our findings were consistent with the other published cost-effectiveness analyses which also showed that combination therapy led to the potential incremental cost and benefit of QALYs gained, leading to cost-effectiveness of the new intervention. For example, a study in Canady by [@B10] showed that, over a lifetime, the combination therapy led to an ICER of US\$20,224 per QALY gained over 10-year time horizon and was considered cost-effective for 99.6% of probability at a willingness-to-pay threshold of CAN\$50,000 (US\$39,752) per QALY. In the United Kingdom, [@B28] constructed a Markov state transition model measured by QALYs for patients aged ≥50 years with BPH and moderate to severe symptoms. While cumulative discounted costs per patient were higher with combination therapy than with tamsulosin alone, QALYs were also higher. Their probabilistic sensitivity analysis revealed that the probability of combination therapy being cost-effective lied in the range of 78--88%. In a Norwegian economic model, [@B5] used a semi-Markov model to project costs and utility outcomes over two time horizons, namely 4 years and lifetime. ICERs of combination were US\$12,374 and US\$6,871 over 4 years and lifetime, respectively. Another Japanese study on the pharmacoeconomic evaluation of combination therapy suggested that such treatment with alpha blocker and dutasteride in BPH patients would be more cost-effective than alpha blockers alone in patients with moderate to severe symptoms ([@B27]). The ICERs for combination therapy versus monotherapy calculated at 4 years and 10 years were US\$47,581 and US\$55,532/QALY gained, respectively, both below the acceptable ICER threshold in Japan.

The present study has several limitations. Firstly, in our Markov model, due to data availability, we did not separate the state of symptomatic BPH into patients with mild, moderate and severe symptoms according to IPSS score. Instead, these 3 groups of patients were analyzed as a single group. Such categorization might have made the prediction of AUR probability less precise. As shown in OWSA, the utility of BPH has substantial impact on ICER. Future study on classification of BPH severity was thus warranted. Secondly, we didn't model the occurrence of adverse events because, as reported in the ComBAT trial, the incidences of adverse events were very similar between combination therapy and monotherapy. In a 2015 study, complete absence of ejaculation was experienced by 23% of patients on combination therapy, and 15% on tamsulosin alone ([@B26]). In the same study, it was found that erection improved in both groups of the patients. Overall, the difference in adverse events between the 2 groups is very small and is expected to have minimal impact on the cost-effectiveness results. Thirdly, we didn't provide analysis from societal perspective which includes indirect costs associated with BPH patients. Indirect costs associated with BPH would include cost from complications of BPH e.g., urinary tract infection, bladder stones, and hematuria ([@B18]; [@B13]). It also would include the loss of productivity of patients and caregivers. The inclusion of those costs is expected to make the cost-effective results even more favorable. Finally, our model were based upon data from literature which dates back to 1990s. While this may not be truly representative of the current situation, we had to rely on such classical studies for the input of the model. Nevertheless, we had also sought experts input to ensure that the model was representative of the current situation in Hong Kong to ensure its applicability.

In conclusion, our study shows that combination therapy as compared with monotherapy is cost-effective due to substantial reduction in the number of AUR and TURP and the associated direct cost in BPH patients in Hong Kong.
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